Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Equity Average (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Equity Average for 9 consecutive years, with $37.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 174.51% to $37.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $37.1 million, a 174.51% increase, with the full-year FY2025 number at -$8.3 million, up 79.22% from a year prior.
  • Equity Average was $37.1 million for Q4 2025 at Akebia Therapeutics, up from $35.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $229.1 million in Q1 2021 to a low of -$49.8 million in Q4 2024.
  • A 5-year average of $32.6 million and a median of $16.8 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: plummeted 618.97% in 2023, then skyrocketed 188.19% in 2025.
  • Akebia Therapeutics' Equity Average stood at $105.6 million in 2021, then plummeted by 93.61% to $6.7 million in 2022, then tumbled by 618.97% to -$35.0 million in 2023, then crashed by 42.26% to -$49.8 million in 2024, then surged by 174.51% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Equity Average are $37.1 million (Q4 2025), $35.4 million (Q3 2025), and $26.9 million (Q2 2025).